Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.